Salvage surgical resection after High-Dose Ifosfamide (HDIF) based regimens in Advanced Soft Tissue Sarcoma (ASTS): A potential positive selection bias - A study of the Spanish group for research on sarcomas (GEIS)

Journal of Surgical Oncology

Volumn 88, Issue 1, 2004, Pages 44-49

  Maurel, Joan ^a   Buesa, José ^b   López Pousa, Antonio ^c   Del Muro, Xavier García ^d   Quintana, María Jesús ^c   Martín, Javier ^e   Casado, Antonio ^f   Martínez Trufero, Javier ^g   De Las Peñas, Ramón ^h   Balañá, Carmen ⁱ  

^a HOSPITAL CLÍNIC   (Spain)

^b HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^c HOSPITAL SANT PAU   (Spain)

^d CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^e HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^f HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^g HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^h Hospital Provincial   (Spain)

ⁱ HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Adult soft tissue sarcoma; High dose ifosfamide; Prognosis; Survival

Indexed keywords

DOXORUBICIN; IFOSFAMIDE;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER LOCALIZATION; CANCER RESEARCH; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG MEGADOSE; FEMALE; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PERFORMANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; SALVAGE THERAPY; SOFT TISSUE SARCOMA; SURVIVAL TIME; TIME; TUMOR GROWTH;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, ALKYLATING; BIAS (EPIDEMIOLOGY); CLINICAL TRIALS, PHASE II; COMBINED MODALITY THERAPY; DOXORUBICIN; FEMALE; FIBROSARCOMA; HISTIOCYTOMA, BENIGN FIBROUS; HUMANS; IFOSFAMIDE; LEIOMYOSARCOMA; LIPOSARCOMA; MALE; MIDDLE AGED; NEUROFIBROSARCOMA; PATIENT SELECTION; PROPORTIONAL HAZARDS MODELS; RESEARCH DESIGN; SALVAGE THERAPY; SARCOMA; SPAIN; SURVIVAL ANALYSIS;

EID: 4744363344     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/jso.20131     Document Type: Article

References (18)

1. Balcerzak SP, Benedetti J, Weiss GR, et al.: Phase II trial of paclitaxel in patients with advanced soft tissue sarcoma: A Southwest Oncology Group study. Cancer 1995;76:2248-2252.
2. Verweij J, Lee SM, Ruka W, et al.: Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: A study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 2000;18:2081-2086.
3. Edmonson JH, Ryan LM, Blum RG, et al.: Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 1993;11:1269-1275.
4. Santoro A, Rouesse J, Steward W, et al.: Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment advanced soft tissue sarcomas: A randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1995;13: 1537-1545.
5. Frustaci S, Buonadonna A, Galligioni E, et al.: Increasing 4-epidoxorubicin and fixed ifosfamide doses plus granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A pilot study. J Clin Oncol 1997;15:1418-1426.
6. Reichardt P, Tilgner J, Hohenberger P, et al.: Dose-intensive chemotherapy with ifosfamide, epirubicin, and filgastrim for adult patients with metastatic or locally advanced soft tissue sarcoma: A phase II study. J Clin Oncol 1998;16:1438-1443.
7. De Pas T, De Braud F, Orlando L, et al.: High-dose ifosfamide plus adriamycin in the treatment of adult advanced soft tissue sarcomas: It is feasible? Ann Oncol 1998;9:917-919.
8. Leyvraz S, Bacchi M, Cerny T, et al.: Phase I multicenter study of combined high-dose ifosfamide and doxorubicin in the treatment of advanced sarcomas. Ann Oncol 1998;9:877-884.
9. Palumbo R, Neumaier C, Cosso M, et al.: Dose-intensive first-line chemotherapy with epirubicin and continuous infusion ifosfamide in adult patients with advanced soft tissue sarcomas: A phase II study. Eur J Cancer 1999;35:66-72.
10. Patel SR, Vadhan-Raj S, Burgess MA, et al.: Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas. Am J Clin Oncol 1998;21:317-321.
11. Van Glabbeke M, Van Oosterom AT, Oosterhuis JW, et al.: Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: An analysis of 2185 patients treated with anthracyclines-containing first-line regimens - An European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 1999;17:150-157.
12. Buesa JM, López-Pousa A, Martín J, et al.: Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcoma of adult: A study of the Spanish Group for Research on Sarcomas. Ann Oncol 1998;9:871-876.
13. López-Pousa A, Buesa J, Montalar J, et al.: First-line doxorubicin and scalated high-dose ifosfamide in advanced soft tissue sarcoma (STS) patients: A phase II study of the Spanish Group for Research on Sarcomas (GEIS). Proc Am Soc Clin Oncol 2000; 19:564.
14. López-Pousa A, Buesa J, García del Muro J, et al.: Sequential high-dose doxorubicin (DX) and high-dose ifosfamide (IF) in advanced previously untreated soft tissue sarcomas of the adult (STS). A multicenter phase II study of the Spanish Group for Research on Sarcomas. Proc Am Soc Clin Oncol 2001;20:353.
15. Van Glabbeke M, di Paola ED, Mouridsen H, et al.: Response to anthracycline based chemotherapy (ABC) and overall survival in patients (PTS) with lung metastases from soft tissue sarcoma (STS): A retrospective study of the EORTC Soft Tissue and Bone Sarcoma Group. Proc Am Soc Clin Oncol 1999;19:542.
16. Van Glabbeke M, Verweij J, Judson I, et al.: Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer 2002;38:543-549.
17. Le Cesne AL, Judson I, Crowther D, et al.: Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group. J Clin Oncol 2000;18:2676-2684.
18. Van Glabbeke M, Van Oosterom AT, Oosterhuis JW, et al.: Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: An analysis of 2185 patients treated with anthracyclines-containing first-line regimens - An European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. Classic Papers Curr Comments 2002;7:821-829.